Ir >>   
Uds: 0
Importe: 0,00
Tengo un usuario, deseo validarme - regístrate
  Buscar/Pesquisa        Búsqueda avanzada  
Herramienta de traducción gratuita de páginas web
Inicio/Iniciação
 > Libros de Medicina  > Oncología  > Oncología general  - Llámanos (+34) 913788918 ¡Gasto de envío gratis para pedidos superiores a 50€ (sin iva) en Península!
Biomarkers For Ovarian Cancer: New Technologies And Targets To Address Persistently Unmet Needs
Biomarkers For Ovarian Cancer: New Technologies And Targets To Address Persistently Unmet Needs
Edición/Edição:
Autores: M. A. Tainsky; A. Lokshin
Editorial:
ISBN: 9781607509783
Formato: Rústica/Paperback
Nº volumenes: 1 Páginas: 140
Año publicación/Ano de publicação: 2012
Disponibilidad/Disponibilidade: 15 días
Precio/Preço : 157,18 € 149,32 € (155,29€ iva incluído)
 (Sea el primero en opinar ) ¿Vas a pedir más de 5 productos? Escríbenos, te enviaremos presupuesto ajustado, envíanos mail

Cómpralos juntos y ahorra
Biomarkers For Ovarian Cancer: New Technologies And Targets To Address Persistently Unmet Needs Oncología. Fundamentos Generales
· Biomarkers For Ovarian Cancer: New Technologies And Targets To Address Persistently Unmet Needs (M. A. Tainsky; A. Lokshin)
· Oncología. Fundamentos Generales (Sérgio Alexandre de Almeida dos Reis)
245,18 € 232,92 €
Descripción/Descrição
Cytoreductive surgery and combination chemotherapy have improved 5 year survival for patients with ovarian cancer, but only 30% are cured due to detection at a late stage and the persistence of dormant, drug resistant cancer cells. Biomarkers could aid in early detection and in personalizing therapy to identify patients who would benefit from conventional or novel targeted drugs. Epithelial ovarian cancers are remarkably heterogeneous, differing in grade, histotype, invasiveness and proliferative index. Low grade Type I serous cancers are associated with mutations of Ras and Raf, but not p53, whereas high grade Type II serous ovarian cancers nearly all have p53 mutations, but rarely mutations of Ras or Raf. An effective screening strategy must detect both types of serous ovarian cancer, as well as the non-serous histotypes. CA125 is expressed by approximately 80% of ovarian cancers, but is elevated in serum at the time of conventional diagnosis in only 50-60% of patients with stage I lesions.

Papers appearing in this issue deal with several technologies and a variety of compounds that could provide serum biomarkers which complement or surpass CA125 for early detection. Among these are proteomic techniques, multiplex assays, antibody arrays, glycans, methylated promoters, miRNAs, and exosomes. Improved imaging strategies are also considered. To personalize therapy with conventional or targeted drugs, prognostic and predictive biomarkers can be used to match particular cancers with particular agents or modalities. Given the expense of anti-vascular therapy, biomarkers with a high negative predictive value would be particularly helpful. Potential biomarkers have been found in endothelial cells from ovarian cancers associated vessels.
Suscripciones
Si desea suscribirse a nuestros boletines gratuitos por favor regístrese como usuario.
Atención clientes
Para realizar sus pedidos o consultas relacionadas con productos llame al:
(+34)91 378 89 18





 

Acerca de los certificados SSL
Nosotros subscribimos Los Principios del código HONcode de la Fundación Salud en la Red Nosotros subscribimos los Principios del código HONcode. Compruébelo aquí.